Kinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine

Clinical and Diagnostic Laboratory Immunology

Volumn 5, Issue 2, 1998, Pages 247-250

  Kilhamn, J ^a   Jertborn, M ^a   Svennerholm, A M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CHOLERA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VACCINATION;

EID: 0031924730     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.5.2.247-250.1998     Document Type: Article

References (33)

1. Åhrén, C., C. Wennerås, J. Holmgren, and A.-M. Svennerholm. 1993. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine 11:929-934.
2. Åhrén, C., M. Jertborn, and A.-M. Svennerholm. Unpublished data.
3. Human. G., U. Bäcker, S. Larsson, B. Melander, and L. Wåhlander. 1983. Oral acelylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur. J. Respir. Dis. 64:405-15.
4. Clemens, J. D., M. Jertborn, D. Sack, B. Stanton, J. Holmgren, M. R. Khan, and S. Huda. 1986. Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine. J. Infect. Dis. 154:175-178.
5. Clemens. J. D., D. A. Sack, J. R. Harris, F. van Loon, J. Chakraborty, F. Ahmed, M. R. Rao, M. R. Khan, M. D. Yunus, N. Huda, B. F. Stanton, B. A. Kay, S. Walter, R. Eeckels, A.-M. Svennerholm, and J. Holmgren. 1990. Field trial of oral cholera vaccine in Bangladesh: results from three-year follow-up. Lancel 335:270-273.
6. Czerkinsky, C., A.-M. Svennerholm, and J. Holmgren. 1993. Induction and assessment of immunity at enteromucosal surfaces in humans: implications for vaccine development. Clin. Infect. Dis. 16(Suppl. 2):S106-S116.
7. Dertzbaugh, M. T., and C. O. Elson. 1991. Cholera toxin as a mucosal adjuvant, p. 119-131. In D. R. Spriggs, and W. C. Koff (ed.), Topics in vaccine adjuvant research. CRC Press, Boca Raton, Fla.
8. Elson, C. O., and M. T. Dertzbaugh. 1994. Mucosal adjuvants, p. 391-402. In P. L. Ogra, M. E. Lamm, J. R. McGhee, J. Mestecky. W. Strober and J. Bienenstock (ed.), Handbook of mucosal immunology. Academic Press San Diego, Calif.
9. Ferrari, V. 1980. Safely and drug interactions of oral acetylcysteine related to utilization data. Eur. J. Respir. Dis. 61(Suppl. 111):151-157.
10. Gaspari, M. M., P. T. Brennan, S. M. Solomon, and C. O. Elson. 1998 A method of obtaining, processing and analyzing human intestinal secretions for antibody content. J. lmmunol. Methods 110:85-91.
11. Gupta, R. K., and G. R. Siber. 1995. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13:1263-1276.
12. Holmgren, J., C. Czerkinsky, N. Lycke, and A.-M. Svennerholm. 1992. Mucosal immunity: implications for vaccine development. Immunobiology 184: 157-179.
13. Holmgren, J., A.-M. Svennerholm, M. Jertborn, J. Clemens, D. A. Sack, R. Salenstedt, and H. Wigzell. 1992. An oral B subunit:whole cell vaccine against cholera. Vaccine 10:911-914.
14. Isolauri, E., J. Joensuu, H. Suomalainen, M. Luomala, and T. Vesikari, 1995. Improved imniunogenicity of oral D × RRV reassortant rotavirus vaccine by Lactobacillus casei GG. Vaccine 13:310-312.
15. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1986. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J. Clin. Microbiol. 24:203-209.
16. Jertborn, M., Svennerholm, A.-M., and J. Holmgren. 1988. Five-year immunologic memory in Swedish volunteers after oral cholera vaccination. J. infect. Dis. 157:374-376.
17. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1992. Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 10:130-132.
18. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1993. Evaluation of different immunization schedules for oral cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine 11:1007-1012.
19. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1994. Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. Vaccine 12:1078-1082.
20. Jertborn, M., A.-M. Svennerholm, and J. Holmgren. 1996. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine 14:1459-1465.
21. Jonson, G., J. Holmgren, and A.-M. Svennerholm. 1991. Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. Microb. Pathog. 11:179-188.
22. Li, A., T. Pal, U. Forsum, and A. A. Lindberg. 1992. Safely and inrmunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers. Vaccine 10:395-404.
23. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301-308.
24. McIntyre, O. R., and J. C. Feeley. 1964. Passive serum protection of the infant rabbit against experimental cholera. J. Infect. Dis. 114:468-475.
25. Olsson, B., M. Johansson, J. Gabrielsson, and P. Bolme. 1988. Pharmacokinctics and bioavailability of reduced and oxidized N-acetylcysteine. Eur. J. Clin. Pharmacol. 34:77-82.
26. Sanchez, J., and ,J. Holmgren. 1989. Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc. Natl. Acad. Sci. USA 86:481-485.
27. Sanchez, J. L., A. F. Trofa, D. N. Taylor, R. A. Kuschner, R. F. DeFraites, S. C. Craig, M. R. Rao, J. D. Clemens, A.-M. Svennerholm, J. C. Sadoff, and J. Holmgren. 1993. Safety and imniunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J. Infect. Dis. 167:1446-1449.
28. Sanchez, J. L., B. Vascuez, R. E. Begue, R. Meza, G. Castellares, C. Cabezas, D. M. Watts, A.-M. Svennerholm, J. C. Sadoff, and D. N. Taylor. 1994. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344:1273-1276.
29. Sheffner, A. L. 1963. The reduction in vitro in viscosity of mucoprolein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann. N. V. Acad. Sci. 106:298-310.
30. Svennerholm, A.-M., and J. Holmgren. 1978. Identification of Escherichia coli heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM1-ELISA) procedure. Curr. Microbiol. 1:19-23.
31. Svennerholm, A.-M., J. Holmgren, R. Black, M. Levine, and M. Merson. 1983. Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J. Infect. Dis. 147:514-522.
32. Svennerholm, A.-M., M. Jertborn, L. Gothefors, A. M. M. M. Karim, D. A. Sack, and J. Holmgren. 1984. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 149:884-893.
33. Svennerholm, A.-M., C. Åhrén, and M. Jertborn. 1997. Vaccines against enterotoxigenic Escherichia coli infections, p. 865-873. In M. M. Levine and G. C. Woodrow (ed.), New generation vaccines. Marcel Dekker, Inc., New York. N.Y.